Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
|
PL |
|
A
|
Athena Technology Acquisition Corp II
AMEX:ATEK
|
US |
|
Y
|
Yara International ASA
XMUN:IU2
|
NO |
|
T
|
Thai Wacoal PCL
SET:WACOAL
|
TH |
|
NowVertical Group Inc
XTSX:NOW
|
CA |
|
Applied Biosciences Corp
OTC:APPB
|
US |
|
T
|
Teco 2030 ASA
OSE:TECO
|
NO |
|
Capricor Therapeutics Inc
F:4LN2
|
US |
|
Auto Italia Holdings Ltd
HKEX:720
|
HK |
|
N
|
Neo Corporate PCL
SET:NEO
|
TH |
|
Exor NV
F:EYX
|
NL |
|
W
|
Winnergy Medical PCL
SET:WINMED
|
TH |
|
Axis Technologies Group Inc
OTC:AXTG
|
US |
|
Spruce Biosciences Inc
OTC:SPRB
|
US |
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BML's stock price target?
Not Available
BML does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Biomed Lublin Wytwornia Surowic i Szczepionek SA?
Projected CAGR
-13%
Over the last 8 years, the compound annual growth rate for Revenue has been 5%. The projected CAGR for the next 1 year is -13%.
What is the Operating Income forecast for Biomed Lublin Wytwornia Surowic i Szczepionek SA?
Projected CAGR
-7%
Over the last 8 years, the compound annual growth rate for Operating Income has been 15%. The projected CAGR for the next 1 year is -7%.
What is the Net Income forecast for Biomed Lublin Wytwornia Surowic i Szczepionek SA?
Projected CAGR
8%
Over the last 8 years, the compound annual growth rate for Net Income has been 64%. The projected CAGR for the next 1 year is 8%.
